Obtain informed consent, document baseline range of motion or curvature degree, review bleeding diathesis or anticoagulant use, and verify absence of active infection at the injection site. No fasting required.
Apply a sterile dressing post-injection. Patient must avoid strenuous activity involving the affected limb or area for 7 days. Monitor for signs of hypersensitivity, excessive swelling, or tendon rupture. Follow-up appointment for secondary manipulation must be strictly adhered to.
Comprehensive Clinical Guide: Intralesional Collagenase Clostridium Histolyticum (Xiaflex)
1. Introduction & Overview
Intralesional Collagenase Clostridium Histolyticum, commercially known as Xiaflex, represents a paradigm shift in the non-surgical management of fibrotic connective tissue disorders. Primarily utilized for Dupuytren’s contracture and Peyronie’s disease, this biological therapeutic agent utilizes a targeted enzymatic approach to disrupt collagen-rich pathological tissue.
Unlike traditional open surgical procedures, which involve fasciectomy or fasciotomy, Xiaflex offers a minimally invasive, office-based intervention. By injecting a precise concentration of collagenase enzymes directly into the palpable cord or plaque, clinicians can induce enzymatic lysis of the collagen matrix, effectively "dissolving" the tethering structures that limit joint range of motion or cause penile curvature. This guide serves as a definitive resource for clinical practitioners, highlighting the intricacies of patient selection, administration, and post-procedural management.
2. Technical Specifications & Mechanism of Action
The Biochemical Engine
Xiaflex consists of a lyophilized mixture of two distinct collagenases (AUX-I and AUX-II) derived from the fermentation of Clostridium histolyticum. These enzymes work synergistically to degrade collagen:
- AUX-I: Targets the N-terminal and C-terminal telopeptides of the collagen molecule.
- AUX-II: Cleaves the internal peptide bonds of the triple-helical region of collagen.
Mechanism of Action
When injected into a collagen-rich cord (Dupuytren’s) or plaque (Peyronie’s), the enzymes initiate a rapid hydrolytic cleavage of the collagen fibrils. This leads to the structural weakening of the pathological tissue. In Dupuytren’s cases, this weakening allows the clinician to perform a "cord disruption" (extension procedure) 24 to 72 hours later, rupturing the cord and restoring joint extension. In Peyronie’s cases, the enzymes reduce the collagen density within the plaque, potentially improving curvature deformity.
| Enzyme Component | Primary Target | Therapeutic Effect |
|---|---|---|
| AUX-I | Telopeptides | Initiates matrix destabilization |
| AUX-II | Triple-helical core | Facilitates rapid structural breakdown |
3. Clinical Indications & Usage
A. Dupuytren’s Contracture
Xiaflex is indicated for adult patients with Dupuytren’s contracture with a palpable cord.
* Patient Selection: Candidates typically exhibit a fixed flexion deformity of the metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joints.
* Clinical Scoring: The Hueston Tabletop Test is often used to assess severity prior to intervention.
B. Peyronie’s Disease
Indicated for adult men with Peyronie’s disease with a palpable plaque and a curvature deformity of at least 30 degrees at the start of therapy.
* Exclusion criteria: Patients with active infection or calcified plaques that preclude needle penetration.
4. Pre-Procedural Preparation & Procedure Steps
Pre-Operative Protocol
- Informed Consent: Must include discussion of potential tendon rupture, edema, and ecchymosis.
- Assessment: Mark the exact location of the cord or plaque using a surgical marker while the patient is in a neutral, relaxed position.
- Sterilization: Cleanse the site with povidone-iodine or chlorhexidine.
The Procedure (Step-by-Step)
- Reconstitution: Reconstitute the lyophilized powder with the provided sterile diluent. Do not shake; gently swirl the vial.
- Injection (Dupuytren’s): Use a 27-gauge, 1/2-inch needle. Inject the dose into the cord at the point of maximum contracture. Ensure the needle is not in the tendon sheath or neurovascular bundle.
- Injection (Peyronie’s): Inject the solution into the target plaque. The injection must be precise to avoid damaging the surrounding erectile tissue.
- Post-Injection Care: Apply a sterile dressing. The patient is instructed to avoid strenuous activity involving the treated extremity or area for 24–48 hours.
5. Post-Op Recovery & Outcomes
The Extension Procedure (Dupuytren’s)
Approximately 24 to 72 hours post-injection, the patient returns for the extension procedure. Local anesthesia (lidocaine) is injected into the skin overlying the cord. The physician applies controlled, firm pressure to the joint to rupture the weakened cord.
Expected Outcomes
- Dupuytren’s: Most patients achieve a reduction in contracture to within 0° to 5° of normal extension.
- Peyronie’s: Clinical trials show a statistically significant reduction in curvature and a decrease in the "bother" score associated with the condition.
6. Risks, Side Effects, and Contraindications
Potential Complications
- Tendon Rupture: A major risk if the enzyme is injected into or near the flexor tendons.
- Allergic Reactions: Anaphylaxis is a rare but documented risk.
- Neurovascular Injury: Potential for nerve damage, particularly the digital nerves in the hand.
- Local Reactions: Significant bruising, swelling, and lymphadenopathy are common.
Contraindications
- Known hypersensitivity to collagenase.
- History of surgery on the same cord (relative contraindication due to altered anatomy).
- Active infection at the injection site.
7. Alternative Treatments
| Condition | Surgical Alternatives | Non-Surgical Alternatives |
|---|---|---|
| Dupuytren’s | Needle Aponeurotomy, Open Fasciectomy | Splinting, Physical Therapy (limited) |
| Peyronie’s | Penile Plication, Grafting/Excision | Penile Traction Therapy, Oral Pentoxifylline |
8. Massive FAQ Section
1. Is Xiaflex a permanent cure?
While highly effective, recurrence of Dupuytren’s contracture can occur. Xiaflex treats the cord, but it does not address the underlying genetic predisposition to myofibroblast proliferation.
2. How many injections are required?
For Dupuytren’s, one injection per cord is standard. For Peyronie’s, a treatment cycle involves multiple injections, typically spaced 6 weeks apart, for up to four cycles.
3. Is the procedure painful?
The injection itself is generally well-tolerated. The follow-up extension procedure for Dupuytren’s can be uncomfortable, which is why local anesthesia is utilized.
4. Can I drive after the procedure?
If the procedure is performed on the hand, driving may be restricted due to swelling and the need for a bulky dressing.
5. What should I do if the finger doesn't fully straighten?
A secondary injection may be considered after a minimum of 4 weeks, depending on the residual contracture.
6. Are there specific medications I should stop before the procedure?
Patients on anticoagulants (blood thinners) may require temporary suspension of their medication to reduce the risk of excessive bruising or hematoma.
7. How soon can I resume sexual activity (Peyronie’s)?
Patients are generally advised to abstain from sexual activity for at least 2 weeks after the injection or until the discomfort has completely resolved.
8. What is the success rate?
Clinical studies indicate that over 60–75% of patients achieve a significant reduction in contracture or curvature deformity.
9. Can Xiaflex be used for other types of scarring?
Currently, Xiaflex is FDA-approved only for Dupuytren’s and Peyronie’s. Its use in other fibrotic conditions (e.g., frozen shoulder, keloids) is considered off-label and is not supported by current standardized guidelines.
10. What signs of infection should I watch for?
Patients should monitor for increasing redness, spreading warmth, fever, or pus-like drainage at the injection site, which would necessitate immediate medical evaluation.
9. Conclusion
Intralesional Collagenase Clostridium Histolyticum (Xiaflex) provides a robust, evidence-based alternative to traditional surgical interventions for fibrotic disease. Its efficacy relies heavily on precise anatomical localization and strict adherence to post-procedural protocols. By minimizing the morbidity associated with surgical fasciotomies and plaque excision, Xiaflex allows for a faster return to daily function and improved quality of life for the affected patient population. Clinicians must maintain rigorous standards of patient selection and procedural accuracy to maximize therapeutic outcomes while mitigating the inherent risks of enzymatic intervention.
Disclaimer: This guide is intended for clinical education purposes only. All procedures must be performed by licensed medical professionals in accordance with manufacturer guidelines and institutional protocols.